Lifecore BiomedicalLFCR -3.78%55 Gross Margin % is 19.24% as of Mar. 2026, which is 26% below its 10-year median of 25.86. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 935 Drug Manufacturers companies, Lifecore Biomedical ranks worse than 82.14% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lifecore Biomedical had a gross margin of 19.24% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Lifecore Biomedical Gross Margin % Related Terms
Lifecore Biomedical Gross Margin % Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFCR vs ANIK, DERM, ASRT: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Lifecore Biomedical (LFCR) has a Gross Margin % of 19.24% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Lifecore Biomedical and its competitors. This is 26% below median its historical median of 25.86. Over the past decade, Lifecore Biomedical's Gross Margin % has ranged from 14.00 to 38.60. According to the industry distribution chart, Lifecore Biomedical ranks #768 out of 935 companies in the Drug Manufacturers industry, placing it in the top 82.1%.
Is Lifecore Biomedical's Gross Margin % too high?
Lifecore Biomedical's current Gross Margin % of 19.24% is 26% below median its 10-year median of 25.86. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 38.60. The Drug Manufacturers industry median Gross Margin % is 48.54. Lifecore Biomedical's value of 19.24% is 60.4% below this industry median. Based on the distribution chart, Lifecore Biomedical ranks #768 out of 935 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Gross Margin % compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #768 out of 935 companies for Gross Margin %. This places Lifecore Biomedical in the lower half of its industry. The industry median Gross Margin % is 48.54. Lifecore Biomedical's value of 19.24% is 60.4% below this benchmark. Historically, Lifecore Biomedical's own Gross Margin % has ranged from 14.00 to 38.60 over the past decade. While the company's 10-year median is 25.86 vs. the industry median of 48.54, Lifecore Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current Gross Margin % of 19.24% is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current Gross Margin % is 19.24%, which is 26% below median its own 10-year median of 25.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current Gross Margin % is 19.24%, which is 26% below median its 10-year median of 25.86 and 60.4% below the Drug Manufacturers industry median of 48.54. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Gross Margin % is 19.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for LFCR:
Gross Margin %: 19.24% (26% below median its 10-year median of 25.86)
GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
Industry Position: 60.4% below the Drug Manufacturers median (#768 of 935)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score
Get the complete analysis for LFCR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
